Intervention Review

You have free access to this content

Efficacy of psychostimulant drugs for amphetamine abuse or dependence

  1. Clara Pérez-Mañá1,*,
  2. Xavier Castells2,
  3. Marta Torrens3,
  4. Dolors Capellà4,
  5. Magi Farre1

Editorial Group: Cochrane Drugs and Alcohol Group

Published Online: 2 SEP 2013

Assessed as up-to-date: 1 AUG 2013

DOI: 10.1002/14651858.CD009695.pub2


How to Cite

Pérez-Mañá C, Castells X, Torrens M, Capellà D, Farre M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.: CD009695. DOI: 10.1002/14651858.CD009695.pub2.

Author Information

  1. 1

    Universitat Autònoma de Barcelona, Human Pharmacology and Clinical Neurosciences Research Group, Hospital del Mar Research Institute-IMIM, Parc de Salut Mar, and Department of Pharmacology, Therapeutics and Toxicology, Barcelona, Catalonia, Spain

  2. 2

    Universitat de Girona, Unit of Clinical Pharmacology, TransLab Research Group, Department of Medical Sciences, Girona, Catalonia, Spain

  3. 3

    Hospital del Mar Research Institute-IMIM, Parc de Salut Mar, Institute of Neuropsychiatry and Addiction, Disorders by Use of Substances Research Group, Barcelona, Spain

  4. 4

    Faculty of Medicine, Universitat de Girona, Unit of clinical pharmacology, Department of medical sciences, Girona, Catalonia, Spain

*Clara Pérez-Mañá, Human Pharmacology and Clinical Neurosciences Research Group, Hospital del Mar Research Institute-IMIM, Parc de Salut Mar, and Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Doctor Aiguader 88, Barcelona, Catalonia, 08003, Spain. cperez@imim.es.

Publication History

  1. Publication Status: New
  2. Published Online: 2 SEP 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
Anderson 2012 {published and unpublished data}
Das 2009 {published and unpublished data}
  • Das M, Santos D, Matheson T, Santos GM, Chu P, Vittinghoff E, et al. Feasibility and acceptability of a phase II randomized pharmacologic intervention for methamphetamine dependence in high-risk men who have sex with men. AIDS 2010;24(7):991-1000.
Elkashef 2008 a {published and unpublished data}
Galloway 2011 {published data only (unpublished sought but not used)}
  • Galloway GP, Buscemi R, Coyle JR, Flower K, Siegrist JD, Fiske LA, et al. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther 2011;89(2):276-82.
Heinzerling 2010 {published and unpublished data}
  • Heinzerling KG, Swanson AN, Kim S, Cederblom L, Moe A, Ling W, Shoptaw S. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2010;109(1-3):20-9.
Konstenius 2010 {published and unpublished data}
  • Konstenius M, Jayaram-Lindström N, Beck O, Franck J. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 2010;108(1-2):130-3.
Longo 2010 {published and unpublished data}
Mancino 2011 {published and unpublished data}
  • Mancino M. Modafinil for methamphetamine dependence. Clinicaltrials.gov (NCT00859573). Results published in April 15, 2011.
Shearer 2009 {published and unpublished data}
Shoptaw 2008 {published and unpublished data}
  • Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 2008;96(3):222-32.
Tiihonen 2007 {published and unpublished data}
  • Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007;164(1):160-2.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
Brensilver 2013 {published data only}
Christian 2007 {published data only}
  • Christian DR, Huber A, Brecht ML, McCann MJ, Marinelli-Casey P, Lord RH, et al. Methamphetamine Treatment Project, Galloway GP. Methamphetamine users entering treatment: characteristics of the methamphetamine treatment project sample. Subst Use Misuse 2007;42(14):2207-22.
Dean 2009 {published data only}
  • Dean AC, London ED, Sugar CA, Kitchen CM, Swanson AN, Heinzerling KG, et al. Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. Drug Alcohol Depend 2009;105(1-2):48-55.
Hartz 2001 {published data only}
  • Hartz DT, Frederick-Osborne SL, Galloway GP. Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis . Drug Alcohol Depend 2001;63(3):269-76.
Marinelli-Casey 2008 {published data only}
  • Marinelli-Casey P, Gonzales R, Hillhouse M, Ang A, Zweben J, Cohen J, et al. Methamphetamine Treatment Project Corporate Authors. Drug court treatment for methamphetamine dependence: treatment response and posttreatment outcomes. J Subst Abuse Treat 2008;34(2):242-8.
McCann 2012 {published data only}
Shearer 2001 {published data only}
  • Shearer J, Wodak A, Mattick RP, Van Beek I, Lewis J, Hall W, Dolan K. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 2001;96(9):1289-96.
Shearer 2010 {published data only}
Whinchell 2012 {published data only}

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
Akhondzadeh L {published data only}
  • Akhondzadeh. Slow-release methylphenidate in the treatment of methamphetamine dependence. International Clinical Trials Registry Platform.
Franck J {published data only}
  • Franck. Clinical trial of sustained release methylphenidate for attention-deficit-hyperactivity-disorder (ADHD) in adult criminal offenders with amphetamine addiction. EU Clinical Trials Register.
Galloway GP a {published data only}
  • Galloway GP. A dose ranging study of modafinil for methamphetamine dependence. ClinicalTrials.gov.
Galloway GP b {published data only}
  • Galloway GP. A randomized, placebo-controlled trial of modafinil for methamphetamine dependence. ClinicalTrials.gov.
Gorgon L {published data only}
  • Gorgon L. Phase 2, double-blind, placebo controlled trial of bupropion for methamphetamine dependence. ClinicalTrials.gov.
Heinzerling K {published data only}
  • Heinzerling K. Study of medical treatment for methamphetamine addiction. ClinicalTrials.gov.
Ling W {published data only}
  • Ling W. Methylphenidate to treat methamphetamine dependence. ClinicalTrials.gov.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
Amato 2005
  • Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. The Journal of Substance Abuse Treatment 2005;28(4):321-9.
Baumann 2012
  • Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.. Neuropsychopharmacology 2012;37:1192-203.
Boutrel 2004
Brackins 2011
  • Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract 2011;24(6):541-50.
Brensilver 2012
  • Brensilver M, Heinzerling KG, Swanson AN, Shoptaw S. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. Drug Alcohol Depend 2012;125(1-2):169-72.
Castells 2007
Castells 2010
Chang 2007
Chen 2010
  • Chen H, Wu J, Zhang J, Hashimoto K. Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence. Current Drug Abuse Reviews 2010;3(4):222-38.
Colfax 2010
De la Garza 2010
  • De La Garza R 2nd, Zorick T, London ED, Newton TF. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug and Alcohol Dependence 2010;106(2-3):173-80.
Degenhardt 2010
Drobes 1999
DSM IV TR
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000.
Egger 1997
  • Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315:629-34.
Eisenberg 2008
  • Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomised controlled trials. Canadian Medical Association Journal 2008;179(2):135-44.
Elkashef 2008 b
Glasner-Edwards 2009
  • Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R, Methamphetamine Treatment Project Corporate Authors. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. The Journal of Nervous and Mental Disease 2009;197(4):225-31.
Glasner-Edwards 2010
Guy 1976
  • Guy W. In: Clinical Global Impressions: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute for Mental Health, 1976.
Hamilton 1959
  • Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50-5.
    Direct Link:
Hamilton 1960
Herin 2010
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
Howell 2008
Karila 2010
King 2005
  • King GR, Ellinwood EH. Amphetamines and other stimulants. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG editor(s). Substance Abuse. A Comprehensive Textbook. 4th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:207-22.
Kirkpatrick 2012 a
  • Kirkpatrick MG, Gunderson EW, Perez AY, Haney M, Foltin RW, Hart CL. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2012;219:109-22.
Kirkpatrick 2012 b
Knapp 2007
Koob 2009
  • Koob GF. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropsychopharmacology 2009;56(1):18-31.
Kosman 1968
  • Kosman ME, Unna DR. Effects of chronic administration of the amphetamines and other stimulants on behavior. Clinical Pharmacology & Therapeutics 1968;9:240-54.
Lee 2008
Makris 2007
  • Makris AP, Rush CR, Frederich RC, Taylor AC, Kelly TH. Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults. Experimental and Clinical Psychopharmacology 2007;15(2):123-33.
Martin 1971
  • Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clinical Pharmacology & Therapeutics 1971;12(2):245-58.
McGregor 2008
  • McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. The Journal of Substance Abuse Treatment 2008;35(3):334-42.
Moeller 2008
  • Moeller FG, Schmitz JM, Herin D, Kjome KL. Use of stimulants to treat cocaine and methamphetamine abuse. Current Psychiatry Report 2008;10(5):385-91.
Newton 2005
  • Newton TF, De La Garza R, Kalechstein AD, Nestor L. Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharmacology Biochemistry and Behaviour 2005;82(1):90-7.
Newton 2006
  • Newton TF, Roache JD, De la Garza R 2nd, Fong T, Wallace CL, Li SH, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006;31(7):1537-44.
NIDA 2006
  • Methamphetamine: Abuse and Addiction. NIDA Research Report 2006; Vol. NIH Publication Number 06-4210.
Pérez-Mañá 2011
  • Pérez-Mañá C, Castells X, Vidal X, Casas M, Capellà D. Efficacy of indirect dopamine agonists for psychostimulant dependence: a systematic review and meta-analysis of randomized controlled trials. The Journal of Substance Abuse Treatment 2011;40(2):109-22.
Robinson 1985
  • Robinson JB. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl. Biochemical Pharmacology 1985;34(23):4105-8.
Rossetti 1992
  • Rossetti ZL, Hmaidan Y, Gessa GL. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. European Journal of Pharmacology 1992;221:227-34.
Salo 2011
  • Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Research 2011;186(2-3):356-61.
Shearer 2007
Shearer 2008
Shoptaw 2009
Somoza 1995
  • Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J, Cohen M. In search of a universal drug craving scale. Proceedings of the Annual Meeting of the American Psychiatric Association, Miami, Florida. 1995.
Srisurapanont 2001
  • Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD003022]
UNODC 2012
  • UNODC. World Drug Report 2012. United Nations Publication, Sales No. E.12.XI.1 2012.
WHO Technical Briefs 2011
  • Patterns and consequences of the use of amphetamine-type stimulants. http://www.who.int/hiv/pub/idu/ats_brief1.pdf. A ccessed 1 July 20 1 1 .
Wilens 2004
  • Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk,and treatment issues. Psychiatric Clinics of North America 2004;27(2):283-301.
Xi 2008
  • Xi ZX, Gardner EL. Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Current Drug Abuse Reviews 2008;1(3):303-27.
Zahniser 2009